MONTREAL and TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or "the Company"), a leader in aerial and defense solutions, is pleased to announce the appointment of Lieutenant-General (Ret’d) Christopher J. Coates, CMM, MSM, CD, LOM, to its Board of Advisors. His appointment strengthens the Company’s defense expertise as Volatus advances its vision to support the Canadian Armed Forces (CAF), NORAD modernization, and allied defense ...

Ness Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that it and its majority-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), have entered into definitive agreements with institutional investors (the “Investors”) for an investment in Eye-Net, based on an Eye-Net pre-money valuation of $55 million. The gross proceeds of the investment amounted to $3 million, before d ...

JACKSONVILLE, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ: LSTR), a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation logistics services, announced that on December 3, 2025, its Board of Directors declared a special one-time cash dividend in the amount of $2.00 per share, payable on January 21, 2026 to stockholders of record as of the close of business on January 6, 2026. “Landstar’s strong balance ...

| Title: | Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients | | --- | --- | | | Hope for Safer, More Effective Breast Cancer Therapy Combinations | | Date: | Thursday, December 11, 2025 | | Time: | 5 p.m. – 6:30 p.m. CT | | Abstract/Poster: | #801 Poster PS4-10-15 | | Presenting author: | Lewis Bender, M.S. M.A. M.B.A., Intensity Therapeutics | | Title: | Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early Stage Triple Negative Breas ...

SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States. The BalanceTutor is the only known rehabilitati ...

MCLEAN, Va., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. ("Cycurion" or the "Company") (NASDAQ: CYCU), a publicly traded leader in technology and staffing solutions for the public sector, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,657,460 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 3,314,920 shares of common stock at an effective combined price of $3. ...

Core Insights - Polyrizon Ltd. is advancing its development of non-pharmacological solutions for respiratory defense, particularly through its innovative hydrogel-based nasal spray technology [1][4][8] Company Overview - Founded by Tomer Izraeli, Polyrizon focuses on creating smarter nasal protection to address gaps in traditional nasal sprays, which often provide only temporary relief [2][4] - The company's proprietary Capture & Contain™ (C&C) platform utilizes a bio-adhesive hydrogel to form a protective barrier in the nasal cavity, effectively trapping airborne particles [2][4] Product Development - Polyrizon's flagship product, PL-14 Allergy Blocker, is designed to provide drug-free protection against allergens by forming a moisturizing barrier in the nasal cavity [3][4] - The company has achieved significant manufacturing milestones, successfully producing larger-scale batches of PL-14 under controlled conditions, confirming its ability to scale for clinical trials and future commercial production [5][6] Market Potential - The seasonal allergic rhinitis market is projected to grow from USD 11.14 billion in 2025 to USD 13.79 billion by 2032, with a CAGR of 3.1% [4] - The global influenza market is expected to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029, indicating a strong demand for innovative respiratory solutions [4] Future Directions - Polyrizon aims to expand the applications of its C&C platform beyond allergies to include viral protection against respiratory pathogens [7] - The company is also developing its Trap & Target™ (T&T) technology for targeted delivery of active pharmaceutical ingredients, which could address various medical conditions [7][8]

Core Points - FuelCell Energy, Inc. will release its fourth quarter and fiscal year 2025 results on December 18, 2025, before the stock market opens [1] - A conference call with investors will take place at 10:00 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] - Participants can access the live call via webcast or telephone, with a replay available approximately two hours after the call [2] Company Overview - FuelCell Energy, Inc. offers clean and reliable energy solutions that enable customers to access power quickly and manage emissions while maintaining operations [3] - The company provides efficient, scalable, and fuel-flexible systems that operate on natural gas, biofuels, or hydrogen, delivering steady baseload electricity globally [3] - With over 55 years of experience and nearly 200 modules deployed, FuelCell Energy assists customers in achieving their energy goals [3]

Core Insights - Plus Therapeutics, Inc. presented positive clinical data for REYOBIQ at the WFNOS/SNO Annual Meeting, indicating no dosage limiting toxicity in the ReSPECT-LM trial and promising safety and efficacy in the ReSPECT-GBM trial [1][2][12] - The company aims to improve survival rates for patients with central nervous system (CNS) cancers through its expanding clinical data set and the CNSide diagnostic portfolio [2][12] ReSPECT-LM Trial - The Phase 1 trial for Leptomeningeal Metastases (LM) showed that REYOBIQ was well-tolerated at a maximum dose of 66 mCi, with a recommended Phase 2 dose of 44.1 mCi [7] - Enrollment in Cohort 1 has begun, with three patients treated without dose limiting toxicity [7] ReSPECT-GBM Trial - The Phase 1/2 trial for recurrent Glioblastoma (GBM) has enrolled 24 out of a planned 34 patients, with a recommended Phase 2 dose of 22.3 mCi based on safety profiles [8] - Efficacy data indicated a median overall survival of 17 months for patients receiving ≥100 Gy, compared to 6 months for those receiving <100 Gy, surpassing historical outcomes for bevacizumab monotherapy [14] Safety Profile - Most treatment-related adverse events in both Phase 1 and 2 trials were Grade 1 or 2, with no treatment-related deaths reported [9] - Common adverse events included lymphopenia (7.9%), cognitive disorder (7.0%), and headache (7.0%) [9] Imaging and Efficacy - MRI combined with SPECT imaging biomarkers effectively evaluates overall survival response in recurrent GBM treatment, aiding in personalized patient planning [12][14] - REYOBIQ's efficacy is positively correlated with treatment coverage ratio and progression-free survival, while negatively correlated with tumor volume [14] About REYOBIQ - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed for targeted high-dose radiation in CNS tumors, with potential advantages over currently approved therapies [15] - The drug is being evaluated in multiple clinical trials, including ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC, with funding support from various institutions [15]

Core Insights - ZenaTech, Inc. has signed an offer to acquire a well-established surveying and spatial services firm in Queensland, Australia, marking its first entry into the Australian market and supporting its global expansion strategy [1][2] - The acquisition aligns with ZenaTech's long-term vision for expanding its Drone as a Service (DaaS) platform in the Asia-Pacific region, particularly in the mining and industrial sectors [2][3] Company Overview - ZenaTech specializes in AI drone technology, DaaS, enterprise SaaS, and Quantum Computing solutions, focusing on mission-critical business applications [5] - The company has been operational since 2017 and has developed a portfolio that enhances operational efficiencies and cost savings across various sectors, including law enforcement, health, government, and industrial applications [5] Acquisition Details - The target firm is recognized for its high-quality outcomes in public and private sector projects and has advanced capabilities in drone-enabled survey workflows, LiDAR, and mobile mapping [2][3] - This acquisition will enable ZenaTech to extend its DaaS offerings into the natural resources sector, integrating advanced spatial capabilities with its drone solutions [3] Strategic Implications - The acquisition is expected to provide ZenaTech with a strategic entry point into the APAC region, allowing it to deliver advanced drone-enabled solutions to government and commercial clients [2] - By acquiring established service companies, ZenaTech aims to build a global, multi-service DaaS network that leverages existing customer bases and generates recurring revenue [4]